Achilles Therapeutics (NASDAQ: ACHL) has announced its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and deregister from the SEC. The company has scheduled a General Meeting for March 20, 2025 to obtain shareholder approval for commencing a members’ voluntary liquidation.
The company plans to file Form 25 with the SEC on March 10, 2025, with the final trading day expected to be March 20, 2025. Post-delisting, ADS trading will be to privately negotiated sales and potentially over-the-counter markets, though continued trading is not guaranteed. The company will file Form 15 around March 20, 2025, suspending its SEC reporting obligations, with…
